Saul Priceman, Ph.D., is an associate professor and associate director of Translational Sciences & Technologies in the T Cell Therapeutics Research Laboratories at City of Hope, as well as a trained tumor immunologist with expertise in T cell biology and cancer immunotherapy. He is developing chimeric antigen receptor (CAR)-based T cell immunotherapy primarily for solid cancers, with a strong focus on metastatic disease in breast, prostate and pancreatic cancer.
Dr. Priceman received his B.S. in microbiology at University of California Santa Barbara, and his Ph.D. in molecular and medical pharmacology at University of California Los Angeles.
Dr. Priceman is a principal investigator on multiple grants including from the National Institute of Health (NIH), Department of Defense, California Institute for Regenerative Medicine, Prostate Cancer Foundation, and the National Comprehensive Cancer Network, leading the development of solid tumor CAR T cell therapies and working with his team optimizing new immunotherapy strategies to target tumor immunosuppression.
Dr. Priceman is deeply committed to rapidly advancing potentially paradigm-shifting immunotherapy on behalf of patients with cancer, in part because of personal experiences with family and friends who have struggled with the disease. His overarching goal is to develop a range of effective immunotherapies for solid cancers, based on the powerful CAR T cell platform, with the knowledge that any single therapy will not likely provide durable responses in advanced disease.